12 Result(s)

Article

A prognostic score for patients with lower risk myelodysplastic syndrome

Current prognostic models for myelodysplastic syndromes (MDS) do not allow the identification of patients with lower risk disease and poor prognosis that may benefit from early therapeutic intervention. We eva...

G Garcia-Manero, J Shan, S Faderl, J Cortes, F Ravandi, G Borthakur, W G Wierda… in Leukemia (2008)

Article

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

We investigated efficacy and safety of rabbit anti-thymocyte globulin (rATG), cyclosporine and granulocyte colony-stimulating factor (G-CSF) as first-line therapy for patients with aplastic anemia (AA) and low...

R Garg, S Faderl, G Garcia-Manero, J Cortes, C Koller, X Huang, S York… in Leukemia (2009)

Article

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From 1 January 1980 to 21 May 2008, 91 patients with newly diagnosed AML-M6 wer...

F P S Santos, S Faderl, G Garcia-Manero, C Koller, M Beran, S O'Brien, S Pierce… in Leukemia (2009)

Article

Low expression of PP2A regulatory subunit B55α is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients

The regulation of protein kinase B (AKT) is a dynamic process that depends on the balance between phosphorylation by upstream kinases for activation and inactivation by dephosphorylation by protein phosphatase...

P P Ruvolo, Y H Qui, K R Coombes, N Zhang, V R Ruvolo, G Borthakur, M Konopleva… in Leukemia (2011)

Article

Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies

F J Giles, N Vey, D Rizzieri, F Ravandi, T Prebet, G Borthakur, T F Jacobsen… in Leukemia (2012)

Article

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

Y Boumber, H Kantarjian, J Jorgensen, S Wen, S Faderl, R Castoro, J Autry… in Leukemia (2012)

Article

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

P Jain, H Kantarjian, F Ravandi, D Thomas, S O'Brien, T Kadia, J Burger… in Leukemia (2014)

Article

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

F Ravandi, C Arana Yi, J E Cortes, M Levis, S Faderl, G Garcia-Manero… in Leukemia (2014)

Article

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

Decitabine may open the chromatin structure of leukemia cells making them accessible to the calicheamicin epitope of gemtuzumab ozogamicin (GO). A total of 110 patients (median age 70 years; range 27–89 years)...

N Daver, H Kantarjian, F Ravandi, E Estey, X Wang, G Garcia-Manero, E Jabbour… in Leukemia (2016)

Article

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a clinical trial, we conducted a study for patients with...

G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju… in Leukemia (2017)

Article

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, Y Alvarado… in Leukemia (2018)